Indication

Generalized lipodystrophy

Generalized lipodystrophy is a rare, heterogeneous group of metabolic disorders characterized by a widespread or near-total absence of adipose tissue. Read more about Generalized lipodystrophy

5 drugs 5 manufacturers

Advertisement

Drugs that treat it

Common Generalized lipodystrophy therapies.

Showing 1–5 of 5 drugs

Filter & compare in the drug finder →Opens the drug finder with Generalized lipodystrophy preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Generalized lipodystrophy.

Generalized lipodystrophy is a rare, heterogeneous group of metabolic disorders characterized by a widespread or near-total absence of adipose tissue.

It encompasses both congenital forms, typically presenting in infancy or early childhood due to pathogenic genetic variants, and acquired forms that develop later in life, often associated with autoimmune conditions or panniculitis.

Pathophysiologically, the profound deficit of functional adipocytes leads to severe hypoleptinemia and ectopic lipid accumulation throughout non-adipose tissues.

This ectopic deposition triggers pronounced metabolic derangements across the endocrine and hepatic systems, clinically manifesting as extreme insulin resistance, early-onset diabetes mellitus, refractory hypertriglyceridemia, acute pancreatitis, hepatic steatosis, and an apparent pseudo-muscular phenotype.

Personalize your experience

Follow Generalized lipodystrophy and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it